AstraZeneca tackles COPD, asthma patients' COVID-19 concerns in new YouTube series

AstraZeneca
AstraZeneca takes its chronic obstructive pulmonary disease and asthma advice directly to patients in a YouTube series of videos on COVID-19 concerns. (AstraZeneca)

AstraZeneca wants to answer questions chronic obstructive pulmonary disease (COPD) and asthma patients might have when it comes to COVID-19. A new, unbranded TV ad invites people with respiratory conditions to a YouTube channel AZ created with a series of explainer videos specific to the novel coronavirus.

The six different videos offer tips and suggestions on topics including monitoring breathing changes, figuring out new exercise options, and navigating telemedicine visits and grocery shopping. The series can be accessed by typing the url directed in the TV ad www.letsbreathetogether.com. 

AstraZeneca created the awareness videos and TV commercial after hearing from concerned patients over the Centers for Disease Control and Prevention warning that people with respiratory conditions are at higher risk of severe illness from COVID-19.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

RELATED: Pharma's reputation has soared during COVID-19 pandemic, poll finds

“We heard loud and clear that many people with respiratory conditions were looking for timely, relevant and easily digestible information on how to navigate a challenging and somewhat confusing time,” Mina Makar, AstraZeneca senior vice president of respiratory and immunology in the U.S., said in an email interview, adding, “COVID-19 is scary for everyone, but for those with asthma and COPD, they are at an increased risk of becoming very sick. If there was ever a time to prioritize respiratory health, it’s now.”

The TV ad began running in late April and will continue on major networks for the next few weeks, he said. The YouTube channel and other social media resources will continue to add information as needed to support people with respiratory conditions, give relevant and relatable advice, and provide directions for possible financial support.

AstraZeneca’s recently reported first-quarter sales haul of $1.56 billion for its respiratory portfolio, a 22% increase year over year, was fueled by Symbicort and Fasenra sales in the U.S. In a call with analysts, AZ noted it saw increased demand across its respiratory portfolio related to COVID-19.

RELATED: Physicians are looking to pharma for COVID-19 comms. Where are they?

Among AZ’s overall COVID-19 efforts, the pharma inked a deal two weeks ago with University of Oxford to secure global manufacturing and distribution rights for the university’s adenovirus-based COVID-19 vaccine, scheduled for late-stage trials by mid-2020.

The British drugmaker is also testing BTK inhibitor Calquence as a potential treatment of COVID-19 cytokine storms in severely ill patients in a phase 2 trial, as well as its diabetes drug Farxiga as a possible treatment to protect against organ damage, now in a phase 3 trial.

Suggested Articles

The only thing certain about 2020 has been uncertainty, leaving almost everyone wondering what might come next.

Operation Warp Speed co-leader Moncef Slaoui is worried that political rhetoric will dissuade Americans from getting vaccinated against COVID-19.

Dr. Reddy’s Laboratories has shut 'key' plants worldwide and all data center services as a preventive measure after detecting a data breach.